Adeptus Biotechnologies Corp. (ADPT) PT Raised to $27 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts ADPT Hot Sheet
Price: $26.64 --0%
Rating Summary:
13 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 20 | New: 16
Rating Summary:
13 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 20 | New: 16
Join SI Premium – FREE
Morgan Stanley analyst Kallum Titchmarsh raised the price target on Adeptus Biotechnologies Corp. (NASDAQ: ADPT) to $27.00 (from $22.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- 'CBOE Holdings (CBOE) Remains Top Pick'; PT Raised to $417 at TD Cowen
- Carter's (CRI) PT Lowered to $33 at UBS
- Vale S.A. (VALE) PT Lowered to $13.50 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
